CONSIDERATIONS TO KNOW ABOUT ABT-046

This novel omics strategy might allow for improved and earlier prediction of anti-CDI recurrence consequences for antibiotics from the clinical enhancement pipeline.A randomized, double-blind, placebo-controlled, one and a number of ascending dose Phase 1 study to find out the security, pharmacokinetics and foodstuff and faecal microbiome effects o